{"protocolSection":{"identificationModule":{"nctId":"NCT03692234","orgStudyIdInfo":{"id":"Homoarginine in Stroke"},"organization":{"fullName":"Universitätsklinikum Hamburg-Eppendorf","class":"OTHER"},"briefTitle":"Homoarginine Supplementation in Patients After Stroke","officialTitle":"Homoarginine in Stroke (HiS) Study","acronym":"HiS"},"statusModule":{"statusVerifiedDate":"2021-06","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-08-22","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-08","type":"ESTIMATED"},"studyFirstSubmitDate":"2018-07-18","studyFirstSubmitQcDate":"2018-09-28","studyFirstPostDateStruct":{"date":"2018-10-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-06-30","lastUpdatePostDateStruct":{"date":"2021-07-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Universitätsklinikum Hamburg-Eppendorf","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study represents a follow-up of the previous study \"Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects\" (NCT02675660). This study will evaluate the applicability of an oral formulation of L-homoarginine to normalize homoarginine blood levels in patients with acute ischemic stroke."},"conditionsModule":{"conditions":["Deficiency; Diet"],"keywords":["homoarginine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"randomized double-blind placebo controlled","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":500,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"placebo","type":"PLACEBO_COMPARATOR","description":"placebo capsules containing lactose - oral once weekly administration for six month","interventionNames":["Other: placebo"]},{"label":"homoarginine","type":"ACTIVE_COMPARATOR","description":"125 mg L-homoarginine supplement - oral once weekly administration for six month","interventionNames":["Dietary Supplement: 125 mg L-homoarginine"]}],"interventions":[{"type":"DIETARY_SUPPLEMENT","name":"125 mg L-homoarginine","description":"capsules for oral supplementation","armGroupLabels":["homoarginine"]},{"type":"OTHER","name":"placebo","description":"capsules for oral supplementation","armGroupLabels":["placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Homoarginine serum concentration","description":"Normalization of homoarginine serum concentration to levels \\>2.1 umol/L.","timeFrame":"six month"}],"secondaryOutcomes":[{"measure":"Intima-media thickness","description":"Intima-media thickness (IMT) measured at both common carotid arteries using an edge detection system. Plaques are defined as protrusion of ≥1.5 mm in common, internal and external carotid artery.","timeFrame":"six month"},{"measure":"National Institute of Health Stroke Scale","description":"National Institute of Health Stroke Scale (NIHSS) will be assessed by a neurologist. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 (normal) and 4 (maximum impairment). The maximum possible score is 42, with the minimum score being a 0.","timeFrame":"six month"},{"measure":"Modified Ranking Scale","description":"Modified Ranking Scale (mRS) is a scale for measuring the degree of disability of a stroke patients. The scale runs from 0 (perfect health) to 6 (death).","timeFrame":"six month"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ischemic stroke (CT or MRI), high-risk transient ischemic attack (ABCD2-score \\>= 4) or acute central retinal artery occlusion\n* serum homoarginine \\</= 2.1 umol/L\n* signed informed consent\n\nExclusion Criteria:\n\n* no acute stroke\n* serum homoarginine \\> 2.1 umol/L\n* heart failure (NYHA \\> 1)\n* chronic kidney disease (GFR \\<60 mL/min)\n* not competent\n* pregnancy, lactation\n* no or withdrawn signed informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Chi-un Choe, MD","role":"CONTACT","phone":"+49407410","phoneExt":"22389","email":"cchoe@uke.de"},{"name":"Edzard Schwedhelm, PhD","role":"CONTACT","phone":"+49407410","phoneExt":"54891","email":"schwedhelm@uke.de"}],"locations":[{"facility":"University Medical Center Hamburg","status":"RECRUITING","city":"Hamburg","zip":"20246","country":"Germany","contacts":[{"name":"Chi-un Che, MD","role":"CONTACT"}],"geoPoint":{"lat":53.57532,"lon":10.01534}}]},"referencesModule":{"references":[{"pmid":"27434056","type":"BACKGROUND","citation":"Atzler D, Schonhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC, Gerloff C, Jaehde U, Jagodzinski A, Boger RH, Choe CU, Schwedhelm E. Oral supplementation with L-homoarginine in young volunteers. Br J Clin Pharmacol. 2016 Dec;82(6):1477-1485. doi: 10.1111/bcp.13068. Epub 2016 Sep 20."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000044342","term":"Malnutrition"}],"ancestors":[{"id":"D000009748","term":"Nutrition Disorders"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M24996","name":"Malnutrition","asFound":"Deficiency; Diet","relevance":"HIGH"},{"id":"M12374","name":"Nutrition Disorders","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]}},"hasResults":false}